Phospholipase A2 expression in prostate cancer as a biomarker of good prognosis: A comprehensive study in patients with long follow-up

Abstract

Background:

Phospholipase A2 (PLA2) is a large family of enzymes involved in the inflammatory process that catalyzes the hydrolysis of membrane phospholipids, leading to the production of free fatty acids and lysophospholipids, starting the arachidonic acid cascade. Their expression has been related to the behavior of several cancers. Our objective is to search for PLA2 expression in prostate cancer (PCa) tissue that correlates with prognosis and survival.

Methods:

Using qRT-PCR, we analyzed the expression levels of PLA2G1B, PLA2G2A, PLA2G2D, PLA2G4A, PLA2G4B, PLA2G4C, PLA2G4D, PLA2G4E, PLA2G4F, PLA2G6, PLA2G7, PLA2G16, PNPLA1, and PNPLA2 in PCa tissue from 108 patients submitted to radical prostatectomy, followed by a mean time of 163 months.

Results:

All PLA2 was overexpressed in PCa compared to normal tissue. Interestingly, higher expression of some PLA2 was related to favorable prognostic factors: lower levels of PSA (PLA2G2A, PLA2G4D), lower rates of lymph node metastasis (PLA2G16 and PLA2G1B), and organ-confined disease (PLA2G4A). Most importantly, PLAG4B was independently related to longer disease-free survival.

Conclusion:

This is the first study exploring comprehensively the expression levels of PLA2 in PCa, showing that the higher expression of some PLA2 should be used as biomarkers of good prognosis and longer disease-free survival.

Keywords

biomarkers prostate cancer prognosis qRT-PCR survival Phospholipase A2 (PLA2)

Get full access to this article

View all access options for this article.

References

Murakami

Taketomi

Sato

Yamamoto

Secreted phospholipase A2 revisited. J Biochem 2011; 150(3): 233–255.

Murakami

Taketomi

Miki

, et al Emerging roles of secreted phospholipase A2 enzymes: the 3rd edition. Biochimie 2014; 107 Pt A: 105–113.

Chen

Sun

, et al A concise update on the relevance of secretory phospholipase A2 group IIA and its inhibitors with cancer. Med Chem 2017; 13(7): 606–615.

Thun

Namboodiri

Heath

Jr.

Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325(23): 1593–1596.

Rosenberg

Palmer

Zauber

, et al A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83(5): 355–358.

Dong

Patel

Scott

, et al Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett 2006; 240(1): 9–16.

Dannenberg

Altorki

Boyle

, et al Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2(9): 544–551.

Brglez

Lambeau

Petan

Secreted phospholipases A2 in cancer: diverse mechanisms of action. Biochimie 2014; 107 Pt A: 114–123.

Cummings

BS.

Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol 2007; 74(7): 949–959.

10.

Hua

Yao

Vignarajan

, et al Cytosolic phospholipase A2alpha sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Biochim Biophys Acta 2013; 1831(6): 1146–1157.

11.

Zhang

Wei

, et al Tumor cell group via phospholipase A₂ is involved in prostate cancer development. Prostate 2011; 71(4): 373–384.

12.

Niknami

Vignarajan

Yao

, et al Decrease in expression or activity of cytosolic phospholipase A2alpha increases cyclooxygenase-1 action: a cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells. Biochim Biophys Acta 2010; 1801(7): 731–737.

13.

Scott

Sajinovic

Hein

, et al Emerging roles for phospholipase A2 enzymes in cancer. Biochimie 2010; 92(6): 601610.

14.

Vainio

Lehtinen

Mirtti

, et al Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget 2011; 2(12): 1176–1190.

15.

Kune

Watson

LF.

Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48(15): 4399–4404.

16.

Huang

Yan

Guo

, et al Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol 2014; 46(9): 1715–1728.

17.

Dennis

EA.

Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 1994; 269(18): 13057–13060.

18.

Seilhamer

Pruzanski

Vadas

, et al Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem 1989; 264(10): 5335–5338.

19.

Patel

Singh

Niknami

, et al Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin Cancer Res 2008; 14(24): 8070–8079.

20.

Hanahan

Weinberg

RA.

Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646–674.

21.

Rose

Connolly

JM.

Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 1991; 18(3): 243–254.

22.

Chaudry

Wahle

McClinton

, et al Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994; 57(2): 176–180.

23.

Graff

Konicek

Deddens

, et al Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 2001; 7(12): 3857–3861.

24.

Sved

Scott

McLeod

, et al Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res 2004; 64(19): 6934–6940.

25.

Dong

Liu

Scott

, et al Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis 2010; 31(11): 1948–1955.

26.

Dennis

Cao

Hsu

, et al Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 2011; 111(10): 6130–6185.

27.

Yarla

Bishayee

Vadlakonda

, et al Phospholipase A2 isoforms as novel targets for prevention and treatment of inflammatory and oncologic diseases. Curr Drug Targets 2016; 17(16): 1940–1962.

28.

Mirtti

Laine

Hiekkanen

, et al Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality. APMIS 2009; 117(3): 151–161.

29.

Kallajoki

Alanen

Nevalainen

, et al Group II phospholipase A2 in human male reproductive organs and genital tumors. Prostate 1998; 35(4): 263–272.

30.

Oleksowicz

Liu

Bracken

, et al Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer. Prostate 2012; 72(10): 1140–1149.

31.

Epstein

Egevad

Amin

, et al The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40: 244–252.

32.

Livak

Schmittgen

TD.

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25(4): 402–408.

33.

Leung

Chen

Chu

, et al Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci USA 2002; 99(25): 16203–16208.

34.

Cormier

Hong

Halberg

, et al Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 1997; 17(1): 88–91.

35.

Hua

Vignarajan

Yao

, et al AKT and cytosolic phospholipase A2alpha form a positive loop in prostate cancer cells. Curr Cancer Drug Targets 2015; 15(9): 781–791.

36.

Chiba

Michibata

Wakimoto

, et al Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A2, cPLA2delta, induced in psoriatic skin. J Biol Chem 2004; 279(13): 12890–12897.

37.

Tao

Zhang

, et al A family based study of the genetic association between the PLA2G4D gene and schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2005; 73(6): 419–422.

38.

Ning

GuoJi

, et al Meta-analysis of differentially expressed genes in autism based on gene expression data. Genet Mol Res 2015; 14(1): 2146–2155.

39.

Parry

Rose-Zerilli

Gibson

, et al Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One 2013; 8(12): e83244.

40.

Leslie

CC.

Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2. Prostaglandins Leukot Essent Fatty Acids 2004; 70(4): 373–376.

41.

Yao

Xie

Kiang

, et al Targeting of cytosolic phospholipase A2α impedes cell cycle re-entry of quiescent prostate cancer cells. Oncotarget 2015; 6(33): 34458–34474.

42.

Duncan

Sarkadi-Nagy

Jaworski

, et al Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA). J Biol Chem 2008; 283(37): 25428–25436.

43.

Xia

Bai

Deng

, et al PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer. J Cell Mol Med 2020; 24(21): 12642–1255.

44.

Yanatatsaneejit

Chalermchai

Kerekhanjanarong

, et al Promoter hypermethylation of CCNA1, RARRES1, and HRASLS3 in nasopharyngeal carcinoma. Oral Oncol 2008; 44(4): 400–406.

45.

Yang

Zhang

Jia

, et al High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer. J Thorac Dis 2017; 9(4): 1002–1011.

46.

Jarrard

Schultz

Etheridge

, et al Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection. PLoS One 2019; 14(6): e0218950.

47.

Goonesekere

NCW

Andersen

Smith

, et al Identification of genes highly downregulated in pancreatic cancer through a meta-analysis of microarray datasets: implications for discovery of novel tumor-suppressor genes and therapeutic targets. J Cancer Res Clin Oncol 2018; 144(2): 309–320.

48.

Liu

Zhang

, et al Identification of feature genes for smoking-related lung adenocarcinoma based on gene expression profile data. Onco Targets Ther 2016; 9: 7397–7407.

49.

Cheng

Wang

, et al A novel read-through transcript JMJD7-PLA2G4B regulates head and neck squamous cell carcinoma cell proliferation and survival. Oncotarget 2017; 8(2): 1972–1982.